In short
This article discusses a clinical trial investigating the use of a specialized imaging technique called 68Ga-NODAGA-RGD PET to monitor treatment responses in patients with Age-related Macular Degeneration (AMD). The study aims to evaluate how this advanced imaging method can help assess the effectiveness of antiangiogenic injections in patients with unilateral AMD, potentially improving treatment monitoring and patient outcomes.
At a glance
- Study Type
- Phase 2 clinical trial
- Condition
- Unilateral Age-related Macular Degeneration (AMD)
- Main Objective
- Evaluate 68Ga-NODAGA-RGD PET imaging for monitoring antiangiogenic treatment response
- Imaging Agent
- 68Ga-NODAGA-RGD (68Ga-RGD 15MBq/mL prep)
- Administration Route
- Intravenous injection
- Dosage
- Maximum 2.5 MBq/kg
- Treatment Duration
- 4 months (measurements at M0 and M4)
- Secondary Measurements
- Retinal thickness (OCT), Visual acuity (ETDRS and Parinaud scales)
- Number of Participants
- 20 patients with unilateral AMD
Introduction to 68Ga-NODAGA-RGD
68Ga-NODAGA-RGD is a novel imaging agent being studied for its potential use in patients with Age-related Macular Degeneration (AMD). This compound, also known by its chemical name 5-[4-[(2S,5S,11S,14R)-14-BENZYL-11-(CARBOXYMETHYL)-5-[3-(DIAMINOMETHYLIDENEAMINO)PROPYL]-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAZACYCLOPENTADEC-2-YL]BUTYLAMINO]-2-[4,7-BIS(CARBOXYMETHYL)-1,4,7-TRIAZONAN-1-YL]-5-OXOPENTANOIC ACID RADIOALLEBLED WITH GALLIUM-68, is a radioactive tracer used in Positron Emission Tomography (PET) imaging. It's important to note that this is not a treatment for AMD, but rather a diagnostic tool to help monitor the disease and its response to treatment.
Purpose and Use in AMD
The primary purpose of 68Ga-NODAGA-RGD is to help doctors visualize and measure angiogenic activity in the eyes of patients with AMD. Angiogenesis refers to the formation of new blood vessels, which is a key feature of AMD. By using this imaging agent, doctors hope to: Detect and measure the extent of abnormal blood vessel growth in the eye Monitor how well anti-angiogenic treatments (medications that prevent new blood vessel formation) are working Potentially predict treatment outcomes and guide personalized treatment plans This innovative approach could provide valuable insights into the progression of AMD and the effectiveness of current treatments.
Current Clinical Trial
A Phase 2 clinical trial is currently underway to evaluate the effectiveness of 68Ga-NODAGA-RGD PET imaging in patients with AMD. The main objective of this trial is to assess whether this imaging technique can demonstrate a molecular therapeutic response to intraocular anti-angiogenic injections after three months of treatment in 20 patients with unilateral AMD.
Secondary objectives of the trial include: Measuring the relationship between the 68Ga-NODAGA-RGD PET signal intensity and retinal thickness (measured by Optical Coherence Tomography or OCT) Evaluating the correlation between the PET signal intensity and visual acuity scores (measured using standard eye charts like the ETDRS and Parinaud scales) These measurements will be taken before treatment and after the 6th intraocular injection of the anti-angiogenic agent.
How the Drug is Administered
68Ga-NODAGA-RGD is administered as a solution for injection. It is given intravenously (through a vein) at a maximum dose of 2.5 MBq/kg (megabecquerels per kilogram of body weight). The treatment period is typically short, lasting up to 2 days. This brief exposure is designed to minimize radiation exposure while still providing valuable diagnostic information.
Who Can Participate in the Trial
The clinical trial has specific criteria for who can participate. Eligible participants include: Patients with unilateral AMD (affecting only one eye) Those with at least one focus of choroidal neovascularization (new blood vessel growth) on OCT Patients who have not received any previous anti-angiogenic treatment Individuals who have had a recent initial check-up including OCT and visual acuity measurement Exclusion criteria include: Pregnant or breastfeeding women Patients with bilateral AMD (affecting both eyes) Those with other eye conditions Patients who have already received anti-angiogenic therapy These criteria ensure that the study focuses on a specific group of AMD patients who are most likely to benefit from this new imaging technique.
Potential Benefits and Outcomes
While it's important to note that 68Ga-NODAGA-RGD is still in the research phase, the potential benefits of this imaging technique could be significant for AMD patients. If successful, it could: Provide a more accurate way to assess the progression of AMD Help doctors determine how well treatments are working Allow for more personalized treatment plans based on each patient's specific disease activity Potentially lead to earlier intervention and better outcomes for AMD patients The results of this clinical trial will help determine whether 68Ga-NODAGA-RGD PET imaging could become a valuable tool in the management of AMD in the future.